| Autor: |
Eguzo KN; School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E5 ; Department of Obstetrics and Gynecology, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria., Lawal AK; School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E5., Eseigbe CE; Department of Laboratory Services, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria., Umezurike CC; Department of Obstetrics and Gynecology, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria. |
| Abstrakt: |
Background. Study examined the determinants of mortality among adult HIV patients in a rural, tertiary hospital in southeastern Nigeria, comparing mortality among various ART regimens. Methods. Retrospective cohort study of 1069 patients on ART between August 2008 and October 2013. Baseline CD4 counts, age, gender, and ART regimen were considered in this study. Kaplan-Meier method was used to estimate survival and Cox proportional hazards models to identify multivariate predictors of mortality. Median follow-up period was 24 months (IQR 6-45). Results. 78 (7.3%) patients died with 15.6% lost to followup. Significant independent predictors of mortality include age (>45), sex (male > female), baseline CD4 stage (<200), and ART combination. Adjusted mortality hazard was 3 times higher among patients with CD4 count <200 cells/μL than those with counts >500 (95% CI 1.69-13.59). Patients on Truvada-based first-line regimens were 88% more likely to die than those on Combivir-based first line (95% CI 1.05-3.36), especially those with CD4 count <200 cells/μL. Conclusion. Study showed lower mortality than most studies in Nigeria and Africa, with mortality higher among males and patients with CD4 count <200. Further studies are recommended to further compare treatment outcomes between Combivir- and Truvada-based regimens in resource-limited settings using clinical indicators. |
